creativebiolabs's blog

Scientists from MIT and the Broad Institute have leveraged an existing bacterial system to create a novel strategy for protein delivery that is effective in both human and animal cells. This technique may be used to target certain cell types for the delivery of a wide range of proteins, including those employed in gene editing. This approach shows promise as a reliable vehicle for the transport of therapeutic agents in the fields of gene therapy and cancer treatment.

Baidu and its collaborators made a significant breakthrough in biocomputing when they proposed the mRNA sequence optimization algorithm LinearDesign in the May issue of Nature, a leading international academic journal, which was titled "Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity."

Neoantigens are novel peptide sequences produced by sources such as somatic mutations in tumors. They can trigger recognition by T cells when loaded onto major histocompatibility complex (MHC) molecules. Once recognized, T cells can then signal cell death and mount an immune response to the tumor. Several studies have shown the potential of neoantigen-based immunotherapy for cancer treatment, and numerous clinical trials have been initiated.

Hematopoietic stem cell transplantation (HSCT) is the standard of care for various malignant and non-malignant hematologic diseases and has been used for other diseases such as autoimmune diseases and transplant tolerance induction. In order to achieve implantation of donor HSCs, it is necessary to first deplete the host's own HSCs. However, currently used clearing pretreatment regimens such as radiotherapy are associated with severe myelosuppression and other toxicities such as infections and infertility due to their non-selective nature. Therefore, a safer treatment option is needed.

Recent years have seen increased focus from scientists and healthcare providers on the growing problem of obesity. Although some progress has been made in this area of research, the reasons for the increased prevalence have not been fully elucidated. In this context, two conflicting models of obesity, the carbohydrate-insulin model (CIM) and the energy balance model (EBM), have been proposed and used to explain The two conflicting models, the carbohydrate-insulin model (CIM) and the energy balance model (EBM), have been proposed to explain the etiology of obesity.

The pathogenesis of bipolar disorder (BD), which is characterized by alternating manic and depressive episodes, is not yet clear, and the lack of disease-related animal models is one of the reasons limiting the research on the pathogenesis and therapeutics.

PD-L1 immune checkpoint blockade has become an important treatment approach for lung adenocarcinoma, but the response rate is low. Combination CD47/PD-L1 blockade can increase response rates, but immune-related adverse events (IRAEs) brought on by off-target effects have a significant impact on clinical efficacy. Thus, decreasing IRAEs while increasing the response rate of immunotherapy is a critical scientific topic for enhancing immunotherapy's efficacy.

The oncogene p53 is a key regulator of various cell death pathways such as apoptosis, necrosis, senescence, autophagy, and iron death, so it has been an important anti-cancer target. Previous p53-targeted therapies have mainly focused on inhibiting its E3-linked enzyme MDM2, thereby activating the p53 oncogenic pathway in tumor cells. Since the discovery of Nutlin, the first MDM2 small molecule inhibitor in 2004, various novel MDM2 inhibitors and clinical trials (including monotherapy and combination therapies) have emerged, yet none of them have been approved for marketing by the FDA.

Oncolytic virus (OV) therapy is an emerging novel oncology treatment that selectively replicates in and destroys tumor cells while leaving normal cells unharmed. Thus, in recent years, strategies have shifted toward the development of viral vectors to enhance the immune response within the tumor or to modulate tumor neovascularization, tumor metabolism, and other aspects of the tumor to counteract the malignant tumor microenvironment (TME).

There is mounting proof that the enzyme mitogen-activated protein kinase 4 (MAPK4), which is also known as extracellular-regulated kinase 4 (ERK4), contributes to tumor expansion and treatment resistance.